Cardioprotective role of sphingosine-1-phosphate

Journal of Physiology and Pharmacology

Volumn 62, Issue 6, 2011, Pages 601-607

  Knapp, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Ceramide; Heart infarct; Ischemia reperfusion; Ischemic preconditioning; Post ischemic preconditioning; Sphingolipids; Sphingosine kinase; Sphingosine 1 phosphate; Sphingosine 1 phosphate lyase

Indexed keywords

CERAMIDE; FINGOLIMOD; LYASE; MEMBRANE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN G; PROTEIN KINASE B; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL VIABILITY; ENZYME ACTIVITY; GENE; GENE SILENCING; HEART; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOXIA; ISOLATED HEART; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN METABOLISM; RECEPTOR BINDING; REPERFUSION INJURY; REVIEW; SPHINGOSINE 1 PHOSPHATE LYASE GENE;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LYSOPHOSPHOLIPIDS; PROTEIN BINDING; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84856866392     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 2010; 688: 1-23.
2. Riboni L, Viani P, Bassi R, Prinetti A, Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog Lipid Res 1997; 36: 153-195.
3. Gangoiti P, Camacho L, Arana L, et al. Control of metabolism and signaling of simple bioactive sphingolipids: implications in disease. Prog Lipid Res 2010; 49: 316-334.
4. Huwiler A, Kotler T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochem Biophys Acta 2000; 1485: 63-69.
5. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res 2009; 50(Suppl.): S91-S96.
6. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-195.
7. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007; 48: 2325-2333.
8. Knapp M, Baranowski M, Czarnowski D, et al. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infraction. Med Sci Monit 2009; 15: CR490-CR493.
9. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid-mediated actions. Biochem J 2000; 352: 809-815.
10. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82: 201-211.
11. Zhang B, Tomura H, Kuwabara A, et al. Correlation of high density lipoprotein (HDL)-associated spingosine 1-phosphate with serum levels of HDL-cholesterol and apoproteins. Atherosclerosis 2005; 178: 199-205.
12. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1- phosphate. Trends Endocr Metab 2007; 18: 300-307.
13. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82: 193-200.
14. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010; 6: 489-497.
15. Strub GM, Maceyka M, Hait NC, Milstien, S, Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688: 141-155.
16. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002; 277: 25851-25854.
17. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001; 33: 1713-1717.
18. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007; 293: H3150-H3158.
19. Vessey DA, Li L, Honbo N, Karliner JS. Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Circ Physiol 2009; 297: H1429-H1435.
20. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-518.
21. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun 2008; 375: 425-429.
22. Vessey DA, Kelley M, Li L, et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 2006; 12: BR318-BR324.
23. Jin Z-Q, Zhou H-Z, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282: H1970-H1977.
24. Means CK, Xiao Ch-Y, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292: H2944-H2951.
25. Theilmeier G, Schmidt Ch, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114: 1403-1409.
26. Hofman U, Burkard N, Vogt C, et al. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischemia-reperfusion. Cardiovasc Res 2009; 83: 285-293.
27. Hofman U, Hu K, Walter F, et al. Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischemia-reperfusion. Br J Pharmacol 2010; 160: 1243-1251.
28. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins. J Biol Chem 1999; 274: 27351-27358.
29. Kennedy S, Kane KA, Pyne NJ, Pyne S. Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr Opinion Pharmacol 2009; 9: 194-201.
30. Fukuda Y, Kihara A, Igarashi Y. Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. Biochem Biophys Res Commun 2003; 309: 155-160.
31. Jin Z-Q, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004; 110: 1980-1989.
32. Jin Z-Q, Karliner JS. Low dose N,N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKC epsilon dependent mechanism. Cardiovasc Res 2006; 71: 725-734.
33. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74: 56-63.
34. Jin Z-Q, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res 2007; 76: 41-50.
35. Jin Z-Q, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res 2008; 79: 134-140.
36. Duan HF, Wang H, Yi J, et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007; 18: 1119-1128.
37. Bandhuvula P, Honbo N, Wang G-Y, et al. S1P lyase (SPL): a novel therapeutic target for ischemia/reperfusion injury of the heart. Am J Physiol Heart Circ Physiol 2011; 300: H1753-H1761.
38. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Infcell Biochem 2008; 49: 487-522.
39. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-667.
40. Matsui T, Tao J, Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vitro. Circulation 2001; 104: 330-335.
41. Hla T, Lee M-J, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids-receptor revelations. Science 2001; 294: 1875-1878.
42. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Therapeut 2008; 120: 172-185.
43. Frias MA, James RW, Gerber-Wicht Ch, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc Res 2009; 82: 313-323.
44. Cavalli AM, Ligutti JA, Gellings NM, et al. The role of TNFα and sphingolipid signaling in cardiac hypoxia: evidence that cardiomyocytes release TNFα and sphingosine. Basic Appl Myol 2002; 12: 167-175.
45. Vessey DA, Li L, Kelley M, Zhang J, Karliner JS. Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 2008; 22: 113-118.
46. Unger RH, Orci L. Lipoapotosis: its mechanism and its diseases. Biochim Biophys Acta 2002; 1585: 202-212.
47. Park T-S, Hu Y, Noh H-L, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49: 2101-2112.
48. Finck BN, Han X, Courtois M, et al. Critical role for PPAR-alpha-mediated lipotoxicity in the pathogenesis of cardiac cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-1231.
49. Baranowski M, Blachnio A, Zabielski P, Gorski J. PPARα agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet. J Physiol Pharmacol 2007; 58: 57-72.
50. Baranowski M, Blachnio-Zabielska A, Hinrle T, et al. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res 2010; 51: 74-80.
51. Argaud L, Prigent A-F, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol 2004; 286: H246-H251.
52. Zhang DX, Fryer RM, Hsu AK, Gross GJ, Campbell WB, Li P-L. Production and metabolism of ceramide in normal and ischemic-repefused myocardium of rats. Basic Res Cardiol 2001; 96: 267-274.
53. Beresewicz A, Dobrzyn A, Gorski J. Accumulation of specific ceramides in ischemic/reperfused ceramides; effect of ischemic preconditioning. J Physiol Pharmacol 2002; 53: 371-382.
54. Cui J, Engelman RM, Maulik N, Das DK. Role of ceramide in ischemic preconditioning. J Am Coll Surg 2004; 198: 770-777.
55. Bielawska AE, Shapiro JP, Jiang L, et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am. J Pathol 1997; 151: 1257-1263.
56. Der P, Cui J, Das DK. Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. J Mol Cell Cardiol 2006; 40: 313-320.
57. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008; 75: 1893-1900.
58. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Rev Drug Discov 2010; 9: 883-897.
59. Singer B, Ross AP, Tobias K. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Int J Clin Pract 2011; 65: 887-895.